

DOASENSE Achieves MHRA Registration for Full Suite of DOAC Testing Products, Launches Availability in the UK

HEIDELBERG – 15 October 2025 – DOASENSE GmbH, a leader in specialized diagnostic solutions, announced today that it has successfully achieved registration of its full suite of Direct Oral Anticoagulant (DOAC) testing products with the UK's Medicines & Healthcare products Regulatory Agency (MHRA). This significant milestone clears the path for the immediate availability of DOASENSE's innovative diagnostic tools to healthcare providers across the United Kingdom.

The DOASENSE product line, which includes specialized tests for assessing the presence of DOACs, is now accessible to the UK market through its established distributor, AB Scientific UK. This partnership ensures efficient supply and dedicated technical support for hospitals, clinics, and laboratories.

"Achieving MHRA registration for our complete portfolio is a major accomplishment and underscores our commitment to meeting the highest regulatory standards," said Prof. Dr. Job Harenberg, Managing Director and Co-Founder of DOASENSE GmbH. "We are excited to partner with AB Scientific to bring our critical testing products to UK healthcare professionals. Accurate testing for DOACs is essential for optimizing patient safety, and we are confident our products will make a substantial contribution to patient care in the UK."

The availability of the DOASENSE suite provides UK clinicians with essential tools for personalized DOAC management, particularly in urgent care settings, pre-operative screening, and situations where information on DOAC drug levels is needed.

About the DOASENSE Product Suite:

The IVDR-CE-marked, ANVISA, MHRA and TGA registered DOAC Dipstick is a qualitative all-in-one POCT for both direct factor Xa and thrombin inhibitor DOACs. The test is performed using a urine sample from the patient. The DOAC Dipstick provides results within 10 minutes where they are needed most: at the point-of-care. Specially developed accessories complete the first suite of CE-marked products for rapid point-of-care DOAC testing: Objective documentation of results can be achieved with the compact, automated DOASENSE Reader. And the DOASENSE Control Urines are specially designed reference substances to support quality assurance needs. The in vitro diagnostic products are for professional use only.

About DOASENSE:

DOASENSE is a medical technology company with operations in Heidelberg, Germany. DOASENSE's exclusive, patent protected technology changes the way of testing for direct oral anticoagulants, serving an unmet clinical need.

About AB Scientific:

AB Scientific is a leading distributor of high-quality scientific and medical diagnostics equipment and reagents across the UK.

Contact:

DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany

info@doasense.de

www.doasense.de

AB Scientific UK, 124 City Road, London, EC1V 2NX, United Kingdom

+44 (0)20 8396 6171

+44 (0)20 8396 6233

sales@abscientific.com

www.abscientific.com